Obesity and renal cancer incidence and mortality – a systematic review of prospective cohort studies
More details
Hide details
Department of Urology, Collegium Medicum of the Jagiellonian University, Cracow, Poland
Department of Diabetes and Endocrinology, James Cook University Hospital, Middlesbrough, United Kingdom
Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, United Kingdom
The 1st Department of Urology of the Postgraduate Medical Education Centre at the European Health Centre in Otwock, Poland
Ann Agric Environ Med. 2016;23(1):37–43
Introduction and objective:
There have been many studies published recently on obesity and the risk of renal cancer; however, the epidemiological evidence for such an association has not been consistent. Therefore, a systematic review was conducted of the prospective cohort studies to assess the association between obesity and the risk of renal cancer incidence and death.

Material and Methods:
A search was conducted of the PubMed database and references to published studies from inception until May 2013. Guidelines for Assessing Quality in Prognostic Studies on the Basis of Framework for Potential Biases were followed for quality assessment of studies included in the systematic review.

Twenty eligible studies were identified and included in the systematic review. Among the 20 selected studies, overall study quality was high. Although the evidence from the prospective cohort studies, linking obesity with renal cancer incidence, has not been entirely consistent, there is a convincing body of data for a positive relationship. Moreover, cumulative data is compelling for a strong positive association between obesity and fatal renal cancer.

There is a relatively consistent amount of evidence that obesity increases the risk of renal cancer and fatal renal cancer. Further research is needed as better understanding of mechanisms by which obesity may influence renal cancer development and progression will aid the fostering of strategies for prevention and treatment of one of the most lethal human malignancies.

1. Gundogan K, Bayram F, Gedik V, Kaya A, Karaman A, Demir O, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci. 2013; 9(2): 243–253.
2. Januszek-Trzciąkowska A, Małecka-Tendera E, Klimek K, Matusik P. Obesity risk factors in a representative group of Polish prepubertal children. Arch Med Sci. 2013. DOI: 10.5114/aoms.2013.33328.
3. Kyriazis I, Rekleiti M, Saridi M, Beliotis E, Toska A, Souliotis K, et al. Prevalence of obesity in children aged 6–12 years in Greece: nutritional behaviour and physical activity. Arch Med Sci. 2012 Nov 9;8(5): 859–64. doi: 10.5114/aoms.2012.31296.
4. World Health Organization. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva: World Health Organization; 2009. Accessed: 03.05.2013.
5. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288: 1723–7.
6. Peytremann-Bridevaux I, Faeh D, Santos-Eggimann B. Prevalence of overweight and obesity in rural and urban settings of 10 European countries. Prev Med. 2007; 44: 442–6.
7. Golabek T, Powroznik J, Chlosta P, Dobruch J, Borówka A.The impact of nutrition in urogenital cancers. Arch Med Sci. 2015; 11(2): 411–8.
8. Ertek S, Cicero A. Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. Arch Med Sci. 2012 Nov 9; 8(5):794–804.
9. Zieliński J, Jaworski R, Irga N, Kruszewski JW, Jaskiewicz J. Analysis of selected factors influencing seroma formation in breast cancer patients undergoing mastectomy. Arch Med Sci. 2013 Feb 21; 9(1): 86–92.
10. Adams KF, Leitzmann MF, Albanes D, et al. Body mass and colorectal cancer risk in the NIH-AARP cohort. Am J Epidemiol. 2007; 166(1): 36–45.
11. Olson SH, Trevisan M, Marshall JR, et al. Body mass index, weight gain, and risk of endometrial cancer. Nutr Cancer.1995; 23(2): 141–149.
12. Golabek T, Bukowczan J, Chlosta P, Powroznik J, Dobruch J, Borowka A. Obesity and Prostate Cancer Incidence and Mortality: A Systematic Review of Prospective Cohort Studies. Urol Int. 2014; 92(1): 7–14.
13. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.CA Cancer J Clin. 2011 Mar-Apr; 61(2): 69–90.
14. Häggström C, Rapp K, Stocks T, Manjer J, Bjørge T, Ulmer H, et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One. 2013; 8(2): e57475.
15. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst. 2013 Mar 20; 105(6): 424–32.
16. Zhu Y, Wang HK, Zhang HL, Yao XD, Zhang SL, Dai B, et al. Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma. J Urol. 2013 Feb; 189(2): 447–53.
17. Purdue MP, Moore LE, Merino MJ, Boffetta P, Colt JS, Schwartz KL, et al. An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies. Int J Cancer. 2013 Jun 1; 132(11): 2640–7.
18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21; 6(7): e1000097.
19. Ildaphonse G, George PS, Mathew A. Obesity and kidney cancer risk in men: a meta-analysis (1992–2008). Asian Pac J Cancer Prev. 2009 Apr-Jun; 10(2): 279–86.
20. Mathew A, George PS, Ildaphonse G. Obesity and kidney cancer risk in women: a meta-analysis (1992–2008). Asian Pac J Cancer Prev. 2009 Jul-Sep; 10(3): 471–8.
21. Ildaphonse G, George PS, Mathew A. Obesity and kidney cancer risk in men: a meta-analysis (1992–2008). Asian Pac J Cancer Prev. 2009 Apr-Jun; 10(2): 279–8.
22. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006 Mar 21; 144(6): 427–37.
23. Leiba A, Kark JD, Afek A, Derazne E, Barchana M, Tzur D, et al. Adolescent obesity and paternal country of origin predict renal cell carcinoma: a cohort study of 1.1 million 16 to 19-year-old males. J Urol. 2013 Jan; 189(1): 25–9.
24. Joh HK, Willett WC, Cho E. Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care. 2011 Jul; 34(7): 1552–6.
25. Sawada N, Inoue M, Sasazuki S, Iwasaki M, Yamaji T, Shimazu T, et al. JPHC Study Group. Body mass index and subsequent risk of kidney cancer: a prospective cohort study in Japan. Ann Epidemiol. 2010 Jun; 20(6): 466–72.
26. Adams KF, Leitzmann MF, Albanes D, Kipnis V, Moore SC, Schatzkin A, et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol. 2008 Aug 1; 168(3): 268–77.
27. Song YM, Sung J, Ha M. Obesity and risk of cancer in postmenopausal Korean women. J Clin Oncol. 2008 Jul 10; 26(20): 3395–402.
28. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007 Dec 1; 335(7630): 1134.
29. Luo J, Margolis KL, Adami HO, Lopez AM, Lessin L, Ye W; Women’s Health Initiative Investigators. Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women’s Health Initiative (United States). Am J Epidemiol. 2007 Oct 1; 166(7): 752–9.
30. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007 Oct 15; 166(8): 932–40.
31. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control. 2006 Sep; 17(7): 901–9.
32. Pischon T, Lahmann PH, Boeing H, Tjønneland A, Halkjaer J, Overvad K, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006 Feb 1; 118(3): 728–38.
33. Lukanova A, Björ O, Kaaks R, Lenner P, Lindahl B, Hallmans G, et al. Body mass index and cancer: results from the Northern Sweden Health and Disease Cohort. Int J Cancer. 2006 Jan 15; 118(2): 458–66.
34. Flaherty KT, Fuchs CS, Colditz GA, Stampfer MJ, Speizer FE, Willett WC, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control. 2005 Nov; 16(9): 1099–106.
35. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005 Jul 20; 23(21): 4742–54.
36. Bjørge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol. 2004 Dec 15; 160(12): 1168–76.
37. van Dijk BA, Schouten LJ, Kiemeney LA, Goldbohm RA, van den Brandt PA. Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. Am J Epidemiol. 2004 Dec 15; 160(12): 1159–67.
38. Nicodemus KK, Sweeney C, Folsom AR. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. Int J Cancer. 2004 Jan 1; 108(1): 115–21.
39. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24; 348(17): 1625–38.
40. Møller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 1994; 30A(3): 344–50.
41. Whittemore AS, Paffenbarger RS Jr, Anderson K, Lee JE. Early precursors of site-specific cancers in college men and women. J Natl Cancer Inst. 1985 Jan; 74(1): 43–51.
42. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis. 1979; 32(8): 563–76.
43. Kellerer M, von Eye Corleta H, Mühlhöfer A, Capp E, Mosthaf L, Bock S, et al. Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. Int J Cancer. 1995 Sep 4; 62(5): 501–7.
44. Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S, Dahiya R. Single nucleotide polymorphisms of estrogen receptor alpha in human renal cell carcinoma. Biochem Biophys Res Commun. 2002 Sep 6; 296(5): 1200–6.
45. Okada S, Hamazaki S, Ebina Y, Li JL, Midorikawa O. Nephrotoxicity and its prevention by vitamin E in ferric nitrilotriacetate-promoted lipid peroxidation. Biochim Biophys Acta 1987; 922: 28–33.
46. Toyokuni S, Mori T, Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer. 1994; 57: 123–128.
47. Umemura T, Hasegawa R, Sai-Kato K, et al. Prevention by 2-mercaptoethane sulfonate and N-acetylcysteine of renal oxidative damage in rats treated with ferric nitrilotriacetate. Jpn J Cancer Res. 1996; 87: 882–886.
48. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance—the emerging role of the adipocyte as an endocrine organ. N Engl J Med. 2001; 345: 1345–6.
49. Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue – an update. Horm Metab Res. 2007 May; 39(5): 314–21.
50. Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008 Feb 15; 167(4): 438–46.